ClinicalTrials.gg
Active, not recruitingNCT07163793Updated Nov 18, 2026

Pilot Study of Reduced Venetoclax Exposure

A Phase 2 interventional study of Azacitidine and Decitabine in Acute Myeloid Leukemia in Remission, sponsored by Northwell Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Northwell Health · Phase 2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Primary completion movedStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Planned enrollment
122nd of 211
41 · median 50
Started
2025
with 17 others
Phase 2
105 of 214
40 open now
Primary completion
2027-10
later than 41 of 90 live
Registered
189th of 214
by date

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 122nd largest by planned enrollment of the 211 interventional ones that give a count, is one of 18 that started in 2025, is one of 105 in phase 2, reaches primary completion later than 41 of the 90 other live ones, and was the 189th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Pilot Study of Reduced Venetoclax Exposure

Read the detailed description

A pilot single-arm clinical trial is proposed to assess the primary objective: the tolerability of 14-day Venetoclax cycles in acute myeloid leukemia (AML) patients who have achieved remission and are ineligible for intensive treatment. Participants in the study will transition to a maintenance regimen that reduces the Venetoclax dosage to 14 days per cycle while continuing the hypomethylating agent (HMA) used during induction. Treatment cycles will occur every 28 days. Participants will continue treatment on study until experiencing a grade 4 cytopenic event lasting more than 7 days, an adverse event requiring regimen modification, relapse, or death.

Our primary hypothesis posits that AML patients receiving Venetoclax for 14 days per cycle will exhibit improved treatment tolerability with a reduced rate of grade 4 cytopenia compared to historical data from the VIALE A trial.

03

Conditions studied

  • Acute Myeloid Leukemia in Remission

Keywords

  • AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Stated willingness to comply with all study procedures and availability for the duration of the study
  2. Ability to take oral medication and be willing to adhere to the study regimen
  3. Diagnosed by current WHO or ICC criteria with Acute Myeloid Leukemia and treated for initial induction therapy with one of two regimens:

    1. 5-Azacitidine administered subcutaneously at a dose of 75mg/m2/day X 7 days in combination with VEN (21-28 days/cycle)
    2. Decitabine administered intravenously at a dose of 20mg/m2/day administered in combination with VEN (21-28 days/cycle)
  4. Achieving morphological CR/CRi by bone marrow with \<5% blasts within 3 cycles. See Appendix 2 for definitions.
  5. 0-3
  6. Patient must be able to understand and sign and additional study documents
  7. On C1D1 of trial, patient must have count recovery with >1000, > 50, > 7.7 and without transfusion support for 7 days.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with another drug
  2. Use of growth factor (G-CSF) within the last 14 days prior to C1D1 of trial treatment.
  3. Subject has received treatment prior to induction with the following:

    i. Prior hypomethylating agent or BCL-2 inhibitor for either AML or MDS other than for induction prior to enrollment.

    ii. Prior CAR-T cell therapy. iii. Experimental or investigational drug therapy for 14 days prior to study entry leukemia-directed therapies.

  4. Subject has:

    i. Acute promyelocytic leukemia (APL) with t(15;17). ii. Presence of t(9;22) given the potential indication for concurrent tyrosine kinase therapy.

    iii. Known active CNS involvement with AML.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Active comparator
    Azacytadine + Venetoclax

    Drug: Azacitidine · Drug: Venetoclax

  • Active comparator
    Decitabine + Venetoclax

    Drug: Decitabine · Drug: Venetoclax

Interventions

  • Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study

    Also known as: Vidaza

  • Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off

    Also known as: Dacogen

  • Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine

    Also known as: Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Venetoclax Tolerability Rate

    Tolerability rate defined as the proportion of patients who do not experience grade 4 neutropenia (per the CTCAE v5.0) for over 7 continuous days within the first three cycles of maintenance therapy (90 days). Patient will be evaluated on Day 1 of each cycle. Laboratory studies of prior cycle will be reviewed on that day to identify if patient had \>7 continuous days of cytopenia.

    Time frame: 12 months

Secondary outcomes

  1. Evaluation of Event-Free Survival (EFS)

    EFS: Time from treatment-to-treatment discontinuation, relapse, death of any cause, or lost to follow up (Lost to follow up defined as missing scheduled appointment with no response to 3 phone calls and 1 certified letter).

    Time frame: 12 months

  2. Time to Detriment

    Time to detriment defined as time to meaningful change in the EORTC-QLQ-C30. A meaningful change is defined as a decrease by at least 10 points from their baseline evaluation The EORTC-QLQ0-C30 will be filled out by patient on Day 1 of every cycle for the first 12 cycles of maintenance therapy.

    Time frame: 48 months

  3. Number of pRBC transfusion

    Number of pRBC transfusion received while on trial therapy. Number of platelet transfusion received while on trial therapy. Number of transfusions to be described per patient year. Data collected on Day 1 of every cycle.

    Time frame: 48 months

  4. Evaluate Number of Hospital Admissions

    To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.

    Time frame: 12 months

  5. Rate of adverse events/toxicities

    dverse events/Toxicities related to treatment. List of adverse events/toxicities expected listed in Section 8.

    Time frame: 48 months

  6. Evaluation of Relapse-Free Survival (RFS)

    RFS: Time from treatment initiation to relapse, death, or lost to follow up (Lost to follow up defined as missing scheduled appointment with no response to 3 phone calls and 1 certified letter).

    Time frame: 12 months

  7. Evaluation of Overall Survival (OS)

    OS: Time to death or lost to follow up (Lost to follow up defined as missing scheduled appointment with no response to 3 phone calls and 1 certified letter)

    Time frame: 12 months

  8. Evaluate Number of Days Admitted

    To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.

    Time frame: 12 months

  9. Evaluate Number of Unanticipated lab appointments

    To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.

    Time frame: 12 months

  10. Evaluate Number of Unanticipated clinic visits

    To be evaluated at time of trial therapy discontinuation or 12 cycles of therapy, whichever occurs first.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2027, 26 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 26 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

Start moved once since we started tracking on Sep 25, 2026: Oct 2024 → Aug 2025, on Oct 8, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Oct 2027, on Nov 18, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2028 → Feb 2028, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Sep 9, 2025
StartActual
Aug 26, 2025was Oct 2024
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Feb 2028was Oct 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 7, 2024→Aug 26, 2025
Oct 8, 2026
Primary completion
Oct 2026→Oct 2027
Nov 18, 2026
Study completion
Oct 2028→Feb 2028
Oct 8, 2026
Show all 2 updates
  1. Nov 18, 2026
    Primary completion Oct 2026→Oct 2027
  2. Oct 8, 2026
    Start date Oct 7, 2024→Aug 26, 2025
    Study completion Oct 2028→Feb 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07163793
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Aug 26, 2025
Primary completion
Oct 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Boiclair Stephanie, MD
principal investigator · Northwell Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Decitabine

Start the discussion